To hear about similar clinical trials, please enter your email below
Trial Title:
Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Molecular Testing Panel in the Community Setting ("DINOSAur")
NCT ID:
NCT05692466
Condition:
Stage III Solid Tumors
Stage IV Solid Tumors
Conditions: Official terms:
Neoplasms
Study type:
Observational [Patient Registry]
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
Comprehensive molecular panel test
Description:
Lab test
Arm group label:
Active
Intervention type:
Other
Intervention name:
EORTC QLQ-30
Description:
Quality of life questionnaire
Arm group label:
Active
Summary:
To prospectively identify cancer patients whose tumors express specific molecular markers
targeted by therapeutic agents from a comprehensive molecular test, for the purpose of
selecting the most clinically appropriate treatment in a pragmatic two arm trial.
Criteria for eligibility:
Study pop:
Newly diagnosed cancer patients at the pathology level.
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- Patients who have given informed consent in accordance with the methods and
procedures of this study
- Diagnosis of cancer (stage 3 and stage 4; solid tumors only) requiring medical care
- Patients who have not received treatment related to his/her cancer
- Patients who are willing to sign a release of medical records to the research team
- Male and female patients ≥18 years of age
- Patients under oncology care of a participating site
- Sufficient clinical status for collection of biospecimen samples within usual care
- Patients who have insurance coverage for CMT
Exclusion Criteria:
- Patients considered minors in the jurisdiction where the protocol is conducted.
- Patients who are prisoners and pregnant women.
- Patients who cannot provide consent and did not sign a power of attorney.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Adventist Health Glendale
Address:
City:
Glendale
Zip:
91206
Country:
United States
Status:
Recruiting
Contact:
Last name:
Mihran Shirinian, M.D.
Phone:
818-543-7574
Email:
mshirin@aol.com
Investigator:
Last name:
Mihran Shirinian, M.D.
Email:
Principal Investigator
Start date:
February 1, 2023
Completion date:
November 1, 2025
Lead sponsor:
Agency:
Glendale Adventist Medical Center d/b/a Adventist Health Glendale
Agency class:
Other
Collaborator:
Agency:
Caris Life Sciences
Agency class:
Other
Source:
Glendale Adventist Medical Center d/b/a Adventist Health Glendale
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05692466
